TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Supported Employment for People With Severe Mental Illness in a Swedish Context- A Randomised Controlled Trial
Brief Summary: This project aims at generating evidence of a work-rehabilitation strategy that benefits the people with severe mental illness (SMI) who want to work, increase their sense of well-being and integration in society, decrease their financial dependence and experiences of stigma and discrimination. The project is likely to help form the basis of how to implement the evidence based supported employment (SE)-model, Individual Placement and Support model (IPS), in a Swedish work-rehabilitation context. In the long run, evidence of SE in a Swedish context could help to decrease the period of sick-leave and increase fulfilling and productive lifestyles among people with severe mental illness. In all, the effectiveness of SE can improve the quality of life for the target group, the quality in mental health care rehabilitation and decrease the costs of treatment and care.


Options:
A: Arm Label: Brexipiprazole + ADT; Type: EXPERIMENTAL; Interventions: Drug: OPC-34712, Drug: Placebo, Drug: ADT | Arm Label: Placebo + ADT; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: ADT | Intervention Type: DRUG; Name: OPC-34712; Assigned to Arm(s): Brexipiprazole + ADT | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Brexipiprazole + ADT, Placebo + ADT | Intervention Type: DRUG; Name: ADT; Assigned to Arm(s): Brexipiprazole + ADT, Placebo + ADT
B: Arm Label: Individual Placement and Support-vocational rehabilitation; Type: EXPERIMENTAL; Interventions: Behavioral: Individual Placement and Support-vocational rehabilitation | Arm Label: Vocational rehabilitation available at study site; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Vocational rehabilitation available | Intervention Type: BEHAVIORAL; Name: Individual Placement and Support-vocational rehabilitation; Assigned to Arm(s): Individual Placement and Support-vocational rehabilitation | Intervention Type: BEHAVIORAL; Name: Vocational rehabilitation available; Assigned to Arm(s): Vocational rehabilitation available at study site
C: Intervention Type: DRUG; Name: DVS-233 SR; Assigned to Arm(s): N/A
D: Arm Label: WHI; Type: EXPERIMENTAL; Interventions: Behavioral: Work and Health Initiative | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Medical or Behavioral Intervention | Intervention Type: BEHAVIORAL; Name: Work and Health Initiative; Assigned to Arm(s): WHI | Intervention Type: BEHAVIORAL; Name: Usual Medical or Behavioral Intervention; Assigned to Arm(s): Usual Care

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Supporting Health by Integrating Nutrition and Exercise (SHINE)
Brief Summary: The purpose of this study is to compare two approaches to a diet and exercise-based weight loss program.


Options:
A: Arm Label: Cardiac Rehabilitation plus Transcendental Meditation; Type: EXPERIMENTAL; Interventions: Behavioral: Cardiac Rehabilitation plus Transcendental Meditation | Arm Label: Cardiac Rehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cardiac Rehabilitation plus Transcendental Meditation | Intervention Type: BEHAVIORAL; Name: Cardiac Rehabilitation plus Transcendental Meditation; Assigned to Arm(s): Cardiac Rehabilitation, Cardiac Rehabilitation plus Transcendental Meditation
B: Arm Label: Walking meditation & Walking; Type: EXPERIMENTAL; Interventions: Other: Walking Meditation, Other: Walking | Arm Label: Walking meditation & No exercise; Type: ACTIVE_COMPARATOR; Interventions: Other: Walking Meditation, Other: No exercise | Intervention Type: OTHER; Name: Walking Meditation; Assigned to Arm(s): Walking meditation & No exercise, Walking meditation & Walking | Intervention Type: OTHER; Name: Walking; Assigned to Arm(s): Walking meditation & Walking | Intervention Type: OTHER; Name: No exercise; Assigned to Arm(s): Walking meditation & No exercise
C: Arm Label: Kg-Free; Type: EXPERIMENTAL; Interventions: Behavioral: Kg-Free, Other: Treatment as Usual | Arm Label: Treatment as Usual (TAU); Type: OTHER; Interventions: Other: Treatment as Usual | Intervention Type: BEHAVIORAL; Name: Kg-Free; Assigned to Arm(s): Kg-Free | Intervention Type: OTHER; Name: Treatment as Usual; Assigned to Arm(s): Kg-Free, Treatment as Usual (TAU)
D: Arm Label: SHINE A; Type: EXPERIMENTAL; Interventions: Behavioral: SHINE | Arm Label: SHINE B; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: SHINE | Intervention Type: BEHAVIORAL; Name: SHINE; Assigned to Arm(s): SHINE A, SHINE B

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety And Efficacy Of 2 Doses Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate With Inadequate Response To TNF Inhibitors
Brief Summary: This study will test if CP-690,550 is safe and effective in rheumatoid arthritis patients taking methotrexate who have an inadequate response to tumor necrosis factor inhibitor treatment.


Options:
A: Arm Label: methotrexate + adalimumab; Type: EXPERIMENTAL; Interventions: Drug: Adalimumab | Arm Label: methotrexate + placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): methotrexate + adalimumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): methotrexate + placebo
B: Arm Label: Group I: Placebo + Methotrexate (MTX); Type: EXPERIMENTAL; Interventions: Drug: Golimumab, Other: Placebo, Drug: methotrexate (MTX) | Arm Label: Group II: Golimumab + Methotrexate (MTX); Type: PLACEBO_COMPARATOR; Interventions: Drug: Golimumab, Other: Placebo, Drug: methotrexate (MTX) | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): Group I: Placebo + Methotrexate (MTX), Group II: Golimumab + Methotrexate (MTX) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Group I: Placebo + Methotrexate (MTX), Group II: Golimumab + Methotrexate (MTX) | Intervention Type: DRUG; Name: methotrexate (MTX); Assigned to Arm(s): Group I: Placebo + Methotrexate (MTX), Group II: Golimumab + Methotrexate (MTX)
C: Arm Label: Sequence 1; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Sequence 2; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Sequence 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: CP-690,550 | Arm Label: Sequence 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Sequence 1 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Sequence 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Sequence 3 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Sequence 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Sequence 4 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Sequence 4
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: methotrexate, Drug: etanercept | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: methotrexate, Drug: sulfasalazine, Drug: hydroxychloroquine | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: methotrexate, Drug: etanercept | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: methotrexate, Drug: sulfasalazine, Drug: hydroxychloroquine | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): 1, 2, 3, 4 | Intervention Type: DRUG; Name: sulfasalazine; Assigned to Arm(s): 2, 4 | Intervention Type: DRUG; Name: hydroxychloroquine; Assigned to Arm(s): 2, 4 | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): 1, 3

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Safety And Efficacy Of 2 Doses Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate With Inadequate Response To TNF Inhibitors
Brief Summary: This study will test if CP-690,550 is safe and effective in rheumatoid arthritis patients taking methotrexate who have an inadequate response to tumor necrosis factor inhibitor treatment.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: conventional DMARD combination | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Biological: MTX plus anti-TNF | Intervention Type: DRUG; Name: conventional DMARD combination; Assigned to Arm(s): A | Intervention Type: BIOLOGICAL; Name: MTX plus anti-TNF; Assigned to Arm(s): B
B: Arm Label: 5 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 15 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 30 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 5 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 15 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 30 mg BID | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Golimumab (CNTO 148) with Methotrexate (MTX); Type: EXPERIMENTAL; Interventions: Drug: Golimumab, Drug: MTX | Arm Label: Infliximab with MTX; Type: EXPERIMENTAL; Interventions: Drug: MTX, Drug: Infliximab | Arm Label: Placebo with MTX; Type: PLACEBO_COMPARATOR; Interventions: Drug: MTX, Drug: Placebo | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): Golimumab (CNTO 148) with Methotrexate (MTX) | Intervention Type: DRUG; Name: MTX; Assigned to Arm(s): Golimumab (CNTO 148) with Methotrexate (MTX), Infliximab with MTX, Placebo with MTX | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo with MTX | Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): Infliximab with MTX
D: Arm Label: Sequence 1; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Sequence 2; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Sequence 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: CP-690,550 | Arm Label: Sequence 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Sequence 1 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Sequence 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Sequence 3 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Sequence 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Sequence 4 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Sequence 4

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Topical Budesonide Treatment for Eosinophilic Esophagitis (EoE): Esophageal Medication Distribution, Treatment Response, and Effect on the Adrenal Axis.
Brief Summary: The purpose of this study is to conduct a clinical trial of two formulations of budesonide (nebulized/swallowed versus viscous/swallowed) in patients with EoE to determine if medication contact time and distribution in the esophagus relates to treatment response. The investigators will also determine if there is systemic absorption of these topical steroids. The investigators hypothesize that tissue and symptom response will correlate with esophageal medication contact time and distribution, and that significant systemic absorption will not be seen.


Options:
A: Arm Label: Oral Budesonide Suspension; Type: EXPERIMENTAL; Interventions: Drug: Oral Budesonide Suspension (MB-9) | Arm Label: Matching Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Oral Budesonide Suspension (MB-9); Assigned to Arm(s): Oral Budesonide Suspension | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Matching Placebo
B: Arm Label: RPC4046 Low Dose; Type: EXPERIMENTAL; Interventions: Drug: RPC4046 | Arm Label: RPC4046 High Dose; Type: EXPERIMENTAL; Interventions: Drug: RPC4046 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: RPC4046; Assigned to Arm(s): RPC4046 High Dose, RPC4046 Low Dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluticasone | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: esomeprazole | Intervention Type: DRUG; Name: esomeprazole; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: fluticasone; Assigned to Arm(s): 1
D: Arm Label: inhaled/swallowed budesonide; Type: EXPERIMENTAL; Interventions: Drug: inhaled/swallowed budesonide | Arm Label: viscous/swallowed budesonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: viscous/swallowed budesonide | Intervention Type: DRUG; Name: inhaled/swallowed budesonide; Assigned to Arm(s): inhaled/swallowed budesonide | Intervention Type: DRUG; Name: viscous/swallowed budesonide; Assigned to Arm(s): viscous/swallowed budesonide

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Validating a Delirium Prediction Model for Critically Ill Patients
Brief Summary: The objective of this study is to determine the incidence of delirium in adults patients who are admitted at the critical care unit of a Dutch University Hospital with the mapping of relevant delirium risk factors The primary aim is to validate the investigators' developed delirium prediction model for critical care patients.

A secondary aim is to find differences between delirious patients and non-delirious patients on different aspects of diagnostics, treatment and care, outcome, length of stay, and inflammation.

According to Dutch law, the need to obtain informed consent was waived by the Committee on Research Involving Human Subjects (CMO) of Nijmegen for this observational study (2007/283).


Options:
A: Arm Label: Dexmedetomidine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexmedetomidine | Arm Label: Propofol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Propofol | Intervention Type: DRUG; Name: Dexmedetomidine; Assigned to Arm(s): Dexmedetomidine | Intervention Type: DRUG; Name: Propofol; Assigned to Arm(s): Propofol
B: Arm Label: No sedatation intervention; Type: OTHER; Interventions: Procedure: Sedation or no sedation during mechanical ventilation | Intervention Type: PROCEDURE; Name: Sedation or no sedation during mechanical ventilation; Assigned to Arm(s): No sedatation intervention
C: Arm Label: delirious patients; Type: N/A; Interventions: N/A | Arm Label: non-delirious patients; Type: N/A; Interventions: N/A
D: Intervention Type: DRUG; Name: Arsenic trioxide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Trisenox; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Dance on Patients With Fibromyalgia
Brief Summary: The aim of the present study is to assess the effectiveness of belly dance as a treatment for pain and improving the quality of life of patients with fibromyalgia.

Eighty female patients with fibromyalgia between 18 to 65 years were randomly allocated to a dance group (n=40) and control group (n=40). Patients in the dance group underwent 16 weeks of belly dance twice a week, while the patients in the control group remained on a waiting list. Patients were evaluated with regard to pain (Visual Analogue Scale), function (6 minute walk test), quality of life (Fibromyalgia Impact Questionnaire and SF-36), depression (Beck Inventory), anxiety (State-Trait Anxiety Inventory) and self-image (Body Dysmorphic Disorder Examination) questionnaire. Evaluations were carried out at baseline, after 16 weeks and after 32 weeks.


Options:
A: Arm Label: Strength training; Type: EXPERIMENTAL; Interventions: Behavioral: Strength training | Arm Label: Aerobic exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Aerobic exercise | Intervention Type: BEHAVIORAL; Name: Strength training; Assigned to Arm(s): Strength training | Intervention Type: BEHAVIORAL; Name: Aerobic exercise; Assigned to Arm(s): Aerobic exercise
B: Arm Label: Dance Group; Type: EXPERIMENTAL; Interventions: Behavioral: Dance | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: Other: Control Group | Intervention Type: BEHAVIORAL; Name: Dance; Assigned to Arm(s): Dance Group | Intervention Type: OTHER; Name: Control Group; Assigned to Arm(s): Control Group
C: Arm Label: Tai Chi Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Tai Chi Intervention | Arm Label: Control Intervention; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Control Intervention | Intervention Type: BEHAVIORAL; Name: Tai Chi Intervention; Assigned to Arm(s): Tai Chi Intervention | Intervention Type: BEHAVIORAL; Name: Control Intervention; Assigned to Arm(s): Control Intervention
D: Arm Label: CFQ Qigong training group; Type: ACTIVE_COMPARATOR; Interventions: Other: CFQ Qigong | Intervention Type: OTHER; Name: CFQ Qigong; Assigned to Arm(s): CFQ Qigong training group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Dance on Patients With Fibromyalgia
Brief Summary: The aim of the present study is to assess the effectiveness of belly dance as a treatment for pain and improving the quality of life of patients with fibromyalgia.

Eighty female patients with fibromyalgia between 18 to 65 years were randomly allocated to a dance group (n=40) and control group (n=40). Patients in the dance group underwent 16 weeks of belly dance twice a week, while the patients in the control group remained on a waiting list. Patients were evaluated with regard to pain (Visual Analogue Scale), function (6 minute walk test), quality of life (Fibromyalgia Impact Questionnaire and SF-36), depression (Beck Inventory), anxiety (State-Trait Anxiety Inventory) and self-image (Body Dysmorphic Disorder Examination) questionnaire. Evaluations were carried out at baseline, after 16 weeks and after 32 weeks.


Options:
A: Arm Label: Dance Group; Type: EXPERIMENTAL; Interventions: Behavioral: Dance | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: Other: Control Group | Intervention Type: BEHAVIORAL; Name: Dance; Assigned to Arm(s): Dance Group | Intervention Type: OTHER; Name: Control Group; Assigned to Arm(s): Control Group
B: Arm Label: Group education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Group education | Arm Label: 8-form Yang-style Tai chi program; Type: EXPERIMENTAL; Interventions: Behavioral: 8-form Yang-style Tai chi | Intervention Type: BEHAVIORAL; Name: 8-form Yang-style Tai chi; Assigned to Arm(s): 8-form Yang-style Tai chi program | Intervention Type: BEHAVIORAL; Name: Group education; Assigned to Arm(s): Group education
C: Intervention Type: BEHAVIORAL; Name: cognitive-behavioral therapy; Assigned to Arm(s): N/A
D: Arm Label: CFQ Qigong training group; Type: ACTIVE_COMPARATOR; Interventions: Other: CFQ Qigong | Intervention Type: OTHER; Name: CFQ Qigong; Assigned to Arm(s): CFQ Qigong training group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Dance on Patients With Fibromyalgia
Brief Summary: The aim of the present study is to assess the effectiveness of belly dance as a treatment for pain and improving the quality of life of patients with fibromyalgia.

Eighty female patients with fibromyalgia between 18 to 65 years were randomly allocated to a dance group (n=40) and control group (n=40). Patients in the dance group underwent 16 weeks of belly dance twice a week, while the patients in the control group remained on a waiting list. Patients were evaluated with regard to pain (Visual Analogue Scale), function (6 minute walk test), quality of life (Fibromyalgia Impact Questionnaire and SF-36), depression (Beck Inventory), anxiety (State-Trait Anxiety Inventory) and self-image (Body Dysmorphic Disorder Examination) questionnaire. Evaluations were carried out at baseline, after 16 weeks and after 32 weeks.


Options:
A: Arm Label: placebo (P); Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: phototherapy (FT); Type: EXPERIMENTAL; Interventions: Radiation: Group Phototherapy | Arm Label: phototherapy+Physical activity (FT+A); Type: EXPERIMENTAL; Interventions: Radiation: Phototherapy + Physical activity | Arm Label: Physical activity (A); Type: EXPERIMENTAL; Interventions: Other: Physical activity | Intervention Type: RADIATION; Name: Group Phototherapy; Assigned to Arm(s): phototherapy (FT) | Intervention Type: RADIATION; Name: Phototherapy + Physical activity; Assigned to Arm(s): phototherapy+Physical activity (FT+A) | Intervention Type: OTHER; Name: Physical activity; Assigned to Arm(s): Physical activity (A) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): placebo (P)
B: Arm Label: A. High intensive exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Physical exercise | Arm Label: B. Low-intensive exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Active comparator: low intensive exercise | Intervention Type: BEHAVIORAL; Name: Physical exercise; Assigned to Arm(s): A. High intensive exercise | Intervention Type: BEHAVIORAL; Name: Active comparator: low intensive exercise; Assigned to Arm(s): B. Low-intensive exercise
C: Arm Label: Dance Group; Type: EXPERIMENTAL; Interventions: Behavioral: Dance | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: Other: Control Group | Intervention Type: BEHAVIORAL; Name: Dance; Assigned to Arm(s): Dance Group | Intervention Type: OTHER; Name: Control Group; Assigned to Arm(s): Control Group
D: Arm Label: Physcial exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Physcial activity | Arm Label: Relaxation exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Physcial activity | Intervention Type: BEHAVIORAL; Name: Physcial activity; Assigned to Arm(s): Physcial exercise, Relaxation exercise

Answer: C